MS Product Revenues — Total Revenue
Biogen MS Product Revenues — Total Revenue increased by 4.4% to $957.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.5%, from $953.00M to $957.50M. Over 4 years (FY 2021 to FY 2025), MS Product Revenues — Total Revenue shows a downward trend with a -9.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests successful market adoption, effective pricing strategies, or growth in patient access for MS therapies, while a decrease may indicate increased generic competition, loss of patent exclusivity, or shifting treatment paradigms.
Detailed definition
This metric represents the aggregate gross revenue generated from the sale of the company's portfolio of multiple sclero...
Peer comparison
Comparable to revenue segments for specialized neurology or immunology franchises at other large-cap biopharmaceutical companies, often evaluated against the backdrop of patent cliffs and competitive biosimilar entry.
biib_segment_ms_product_revenues_total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.53B | $1.56B | $1.53B | $1.39B | $1.43B | $1.34B | $1.27B | $1.13B | $1.21B | $1.16B | $1.17B | $1.08B | $1.15B | $1.05B | $1.07B | $953.00M | $1.11B | $1.06B | $917.20M | $957.50M |
| QoQ Change | — | +1.8% | -1.8% | -8.7% | +2.3% | -6.0% | -5.3% | -11.3% | +7.5% | -4.2% | +0.8% | -7.9% | +6.9% | -8.3% | +1.5% | -11.0% | +16.2% | -4.1% | -13.6% | +4.4% |
| YoY Change | — | — | — | — | -6.7% | -13.9% | -17.0% | -19.3% | -15.2% | -13.5% | -7.9% | -4.4% | -4.9% | -9.1% | -8.4% | -11.4% | -3.7% | +0.7% | -14.3% | +0.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's ms product revenues — total revenue?
- Biogen (BIIB) reported ms product revenues — total revenue of $957.50M in Q1 2026.
- How has Biogen's ms product revenues — total revenue changed year-over-year?
- Biogen's ms product revenues — total revenue increased by 0.5% year-over-year, from $953.00M to $957.50M.
- What is the long-term trend for Biogen's ms product revenues — total revenue?
- Over 4 years (2021 to 2025), Biogen's ms product revenues — total revenue has grown at a -9.8% compound annual growth rate (CAGR), from $6.10B to $4.04B.
- What does ms product revenues — total revenue mean?
- The total sales revenue generated from the company's portfolio of multiple sclerosis medications.